Clinical Trials

Burkitt Lymphoma, Lymphoma, B-Cell

NCT06544265 2026-04-14

SynKIR-310 for Relapsed/Refractory B-NHL

36 enrolled

LymphoidSarcoma

Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Waldenstrom Macroglobulinemia, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell, Pyloric Stenosis, Hypertrophic, Dendritic Cell Sarcoma, Interdigitating

NCT01695941 2026-04-13

Alisertib, Bortezomib, and Rituximab in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma or B-cell Low Grade Non-Hodgkin Lymphoma

Lymphoma, B-Cell, Lymphoma, Mantle-Cell

NCT03017820 2026-04-13

A Vaccine (VSV-hIFNβ-NIS) With or Without Cyclophosphamide and Combinations of Ipilimumab, Nivolumab, and Cemiplimab in Treating Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia or Lymphoma

DermatologicLymphoidMyeloidOther hematologic neoplasmPlasma cell

127 enrolled

Immunoblastic Lymphadenopathy, Multiple Myeloma, Mycosis Fungoides, Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Lymphoma, B-Cell, Lymphoma, T-Cell, Lymphoma, T-Cell, Cutaneous, Lymphoma, Large-Cell, Anaplastic

NCT05272384 2026-04-13

Testing the Combination of Nivolumab and ASTX727 for Relapsed or Refractory B-Cell Lymphoma

32 enrolled

Hodgkin Disease, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse

NCT05627245 2026-04-13

Testing the Safety of the Anti-cancer Drugs Tazemetostat and Belinostat in Patients With Lymphomas That Have Resisted Treatment

48 enrolled

DermatologicLymphoid

Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Lymphoma, B-Cell, Lymphoma, T-Cell, Lymphoma, T-Cell, Cutaneous

NCT05784441 2026-04-13

A Study of JNJ-90009530 in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma (r/r B-NHL)

21 enrolled

Recurrence, Lymphoma, B-Cell

NCT01087294 2026-04-08

Administration of Anti-CD19-chimeric-antigen-receptor-transduced T Cells From the Original Transplant Donor to Patients With Recurrent or Persistent B-cell Malignancies After Allogeneic Stem Cell Transplantation

Phase 1 Completed

85 enrolled

Hodgkin Disease, Lymphoma, Non-Hodgkin, Leukemia, B-Cell, Lymphoma, B-Cell

NCT04488354 2026-04-08

Long-term Follow-up Study for Patients Treated With CLBR001 CAR-T

Phase 1 Completed

16 enrolled

Burkitt Lymphoma, Lymphoma, Follicular, Waldenstrom Macroglobulinemia, Neoplasms, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone, Hematologic Neoplasms, Lymphoma, Mantle-Cell

NCT06824701 2026-04-06

TARZAN

Phase 1 Suspended

Recurrence, Lymphoma, B-Cell

NCT06208735 2026-04-03

CLIC-2201 for the Treatment of Relapsed/Refractory B Cell Malignancies

Burkitt Lymphoma, Lymphoma, Non-Hodgkin, Leukemia, B-Cell, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Mantle-Cell

NCT07049432 2026-04-01

CARMEN-803

Phase 1 Withdrawn

Lymphoma, B-Cell

NCT04088890 2026-03-30

Autologous CD22 CAR T Cells in Adults w/ Recurrent or Refractory B Cell Malignancies

Phase 1 Completed

52 enrolled 15 charts

Phase 1 Not yet recruiting

Lymphoma, B-Cell

NCT07101328 2026-03-20

BAF_FRontier-1

215 enrolled

Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse

NCT04629729 2026-03-19

FT819 in Subjects With B-cell Malignancies

54 enrolled

Leukemia, Lymphoma, Leukemia, Lymphocytic, Chronic, B-Cell, Precursor B-Cell Lymphoblastic Leukemia-Lymphoma, Lymphoma, B-Cell

NCT06189391 2026-03-19

MK-1045-001

100 enrolled

Recurrence, Lymphoma, B-Cell

NCT04594642 2026-03-18

A Study of AZD0486 in Subjects With B-Cell Non-Hodgkin Lymphoma

317 enrolled

Lymphoma, Follicular, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse

NCT05397496 2026-03-17

Study of PIT565 in Relapsed and/or Refractory B-cell Malignancies

61 enrolled

Burkitt Lymphoma, Lymphoma, Non-Hodgkin, Lymphoma, B-Cell, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT06026319 2026-03-16

CD79b-19 CAR T Cells in Non-Hodgkin Lymphoma

Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

NCT04970901 2026-03-13

A Study to Evaluate the Safety and Anti-cancer Activity of Loncastuximab Tesirine in Combination With Other Anti-cancer Agents in Participants With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (LOTIS-7)

200 enrolled

Lymphoma, B-Cell

NCT06256484 2026-03-11

A Study to Evaluate the Safety and Preliminary Efficacy of ATA3219 in Participants With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma

Phase 1 Terminated

1 enrolled

Lymphoma, Follicular, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse, Epstein-Barr Virus Infections, Lymphoma, Mantle-Cell

NCT05540340 2026-03-06

A Study of Melphalan in People With Lymphoma Getting an Autologous Hematopoietic Cell Transplant

39 enrolled

Hodgkin Disease, Lymphoma, Lymphoma, Non-Hodgkin, Lymphoma, B-Cell, Lymphoma, T-Cell

NCT05801913 2026-03-05

Genetically Modified T-cells (CMV-Specific CD19-CAR T-cells) Plus a Vaccine (CMV-MVA Triplex) for the Treatment of Intermediate or High Grade B-Cell Non-Hodgkin Lymphoma

15 enrolled

Phase 1 Not yet recruiting

Lymphoma, B-Cell

NCT07451054 2026-03-05

CD45BE-HSPC + CART-45 Cells

42 enrolled

Hodgkin Disease, Lymphoma, B-Cell, Lymphoma, T-Cell

NCT05024045 2026-03-03

Study of Oral LOXO-338 in Patients With Advanced Blood Cancers

LymphoidOther hematologic neoplasmPlasma cell

316 enrolled

Hematologic Diseases, Lymphoma, Non-Hodgkin, Waldenstrom Macroglobulinemia, Multiple Myeloma, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

NCT06173518 2026-03-02

A Study of CD19 Targeted CAR T Cell Therapy in Pediatric Patients With Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia (B ALL) and Aggressive Mature B-cell Non-Hodgkin Lymphoma (B NHL)

30 enrolled

Burkitt Lymphoma, Recurrence, Lymphoma, B-Cell, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT07369492 2026-02-27

Safety and Efficacy Study of BAFF-R CAR-T Cells in Adult Subjects With CD19-Negative Relapsed or Refractory B-Cell Lymphoma

30 enrolled

Lymphoma, B-Cell

NCT05432635 2026-02-23

Genetically Modified T-cells (CMV-Specific CD19-CAR T-cells) Plus a Vaccine (CMV-MVA Triplex) Following Stem Cell Transplantation for the Treatment of Intermediate or High Grade B-cell Non-Hodgkin Lymphoma

15 enrolled

Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Mantle-Cell

NCT05389423 2026-02-19

Pomalidomide and Dose-Adjusted EPOCH +/- Rituximab for HIV-Associated Lymphomas

25 enrolled

Plasmablastic Lymphoma, Burkitt Lymphoma, Lymphoma, Non-Hodgkin, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse, Epstein-Barr Virus Infections

NCT06191887 2026-02-13

B-Cell Activating Factor Receptor (BAFFR)-Based Chimeric Antigen Receptor T-Cells With Fludarabine and Cyclophosphamide Lymphodepletion for the Treatment of Relapsed or Refractory B-cell Hematologic Malignancies

27 enrolled